Research
Hormonal
DPP-IV inhibitors lower blood glucose in type 2 diabetes by preventing the degradation of endogenous incretins (GLP-1 and GIP), offering an oral alternative to injectable GLP-1R agonists.
DPP-IV inhibitors are oral medications that work by stopping the body from breaking down its own natural glucose-lowering hormones (incretins). They are effective in lowering blood glucose and HbA1c in people with type 2 diabetes. They offer an oral alternative to injectable GLP-1R agonists, though they may be less potent.
GoodSupportsHIGH confidence
inhibition of DPP-IV–mediated incretin degradation represents a complementary therapeutic approach, as orally available DPP-IV inhibitors have been shown to lower glucose in experimental diabetic models and human subjects with type 2 diabetes.
Why this rating
Based on review of clinical trials and preclinical studies.
Source
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Daniel J. Drucker · Diabetes Care · 2003
DOI 10.2337/diacare.26.10.2929
narrative_reviewCited 579×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →